PharmAsia News Business Bulletin
You may also be interested in...
Yuhan’s oncology drug lazertinib is set to expand its indications in Korea to the first-line treatment of EGFR mutation-positive advanced NSCLC, based on new top-line Phase III data showing clinical benefits for all patient sub-groups.
Justices cite changing circumstances, constitutional concerns in preventing government from seeking dismissal of a case in which it initially declined to intervene. They also question whether government should intervene before moving to dismiss.
Ulta has increased its fourth quarter and fiscal 2022 full-year outlook on strong third-quarter comparable store sales growth of 14.5%. Mass beauty is outperforming prestige, but CEO David Kimbell said “it’s hard to know for certain if we are starting to see consumers trade down.”